Global Custom Market Research Reports Provider Company

phone

Akcea Therapeutics Inc (AKCA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 11 Apr 2018
  • Number of Pages: 52
  • Category: Pharmaceuticals
  • Country: United States of America
Summary

Akcea Therapeutics Inc (Akcea Therapeutics), a subsidiary of Ionis Pharmaceuticals Inc is a biopharmaceutical company that provides development-stage, advanced, antisense therapies for cardiometabolic lipid disorders. The companys portfolio drugs are designed based on advanced antisense technology. Its pipeline product includes volanesorsen (IONIS-APOCIIIRx), an antisense drug that reduces ApoC-III protein production and lowers triglycerides in patients with dyslipidemia. Akcea Therapeutics also offer products for recurring cardiovascular disease with high lipoprotein, calcific aortic stenosis with high lipoprotein, severe high triglycerides, mixed dyslipidemias and high triglycerides with type 2 diabetes among others. Akcea Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Akcea Therapeutics Inc (AKCA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData

3
List of Tables 5
List of Figures 5
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 11
Licensing Agreements 13
Akcea Therapeutics to Enter into Licensing Agreement with Ionis Pharma 13
Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 15
Equity Offering 17
Akcea Therapeutics Raises USD143.8 Million in IPO 17
Akcea Therapeutics Raises USD50 Million in Private Placement of Shares 19
Akcea Therapeutics Raises USD100 Million in Private Placement of Series A Preferred Stock 20
Akcea Therapeutics Inc - Key Competitors 21
Akcea Therapeutics Inc - Key Employees 22
Akcea Therapeutics Inc - Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Strategy And Business Planning 24
Sep 06, 2017: Akcea Therapeutics Establishes Canadian Subsidiary 24
Financial Announcements 25
Feb 26, 2018: Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2017 25
Nov 06, 2017: Akcea Reports Financial Results and Highlights for Third Quarter 2017 27
Aug 08, 2017: Akcea Reports Financial Results and Highlights for Second Quarter 2017 29
Corporate Communications 31
Sep 05, 2017: Akcea Expands Leadership Team in Preparation for First Commercial Launch 31
May 09, 2017: Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors 33
Mar 28, 2017: Akcea Therapeutics Announces Three Additions to Board of Directors 34
Product News 35
10/16/2017: Akcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia Syndrome 35
07/11/2017: New Data Reveal Hidden Burden of Familial Chylomicronaemia Syndrome 36
03/12/2018: Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo 37
Product Approvals 39
Oct 10, 2017: Akcea Therapeutics Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS) 39
Sep 12, 2017: Akcea Announces Filing of New Drug Submission for Volanesorsen to Health Canada 40
Aug 31, 2017: Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA 42
Jul 27, 2017: Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency 44
Clinical Trials 45
Jan 05, 2018: Akcea Initiates Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular Disease 45
Oct 31, 2017: Akcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRx 47
Aug 08, 2017: Akcea Provides Update on AKCEA-APOCIII-LRx 48
Mar 30, 2017: Akcea Initiates Phase 2 Study of AKCEA-APO(a)-L Rx in Patients with High Lp(a) and Cardiovascular Disease 49
Mar 06, 2017: Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome 50
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List Of Tables

List of Tables
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akcea Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 11
Akcea Therapeutics to Enter into Licensing Agreement with Ionis Pharma 13
Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 15
Akcea Therapeutics Raises USD143.8 Million in IPO 17
Akcea Therapeutics Raises USD50 Million in Private Placement of Shares 19
Akcea Therapeutics Raises USD100 Million in Private Placement of Series A Preferred Stock 20
Akcea Therapeutics Inc, Key Competitors 21
Akcea Therapeutics Inc, Key Employees 22

List Of Figures

List of Figures
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Akcea Therapeutics Inc (Akcea Therapeutics), a subsidiary of Ionis Pharmaceuticals Inc is a biopharmaceutical company that provides development-stage, advanced, antisense therapies for cardiometabolic lipid disorders. The companys portfolio drugs are

View Report

Akcea Therapeutics Inc (Akcea Therapeutics), a subsidiary of Ionis Pharmaceuticals Inc is a biopharmaceutical company that provides development-stage, advanced, antisense therapies for cardiometabolic lipid disorders. The companys portfolio drugs are

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports